Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving patient care through innovative tests, has announced the presentation of new data showcasing the performance of its DecisionDx-Melanoma test in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM). These findings are being shared at the Society of Surgical Oncology 2024 (SSO 2024) Annual Meeting, which is taking place from March 20-23 in Atlanta.
Castle Biosciences has shared new data at the Society of Surgical Oncology 2024 (SSO 2024) Annual Meeting, presenting the performance of its DecisionDx-Melanoma test in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).
Derek Maetzold, President and CEO of Castle Biosciences, highlighted the significance of their DecisionDx-Melanoma test in identifying patients eligible for an SLNB (sentinel lymph node biopsy) with a low risk of being SLN positive, thus potentially avoiding the procedure. The test has also been shown to be a strong and independent predictor of metastasis, further emphasizing its clinical value.
The study presented at SSO 2024 demonstrates that patients who avoided an SLNB procedure based on DecisionDx-Melanoma results had excellent outcomes to date, indicating the test’s ability to guide patients away from unnecessary procedures.
DecisionDx-Melanoma has been supported by over 50 peer-reviewed publications involving more than 10,000 patient samples, showcasing its robust value in guiding risk-aligned patient care. The test addresses two critical clinical questions in managing melanoma: a patient’s risk of recurrence and metastasis, and their individual risk of SLN positivity.
During the meeting, Dr. J. Michael Guenther presented oral data (Oral Presentation Number 62) highlighting three-year outcomes from Castle’s prospective multicenter study involving patients with CM who were considered for an SLNB. The study revealed that patients with a low-risk DecisionDx-Melanoma test result were recurrence-free at three years, demonstrating the test’s ability to guide accurate, risk-aligned clinical decision-making regarding the SLNB procedure.
Additionally, an ePoster (ePoster Number E309) discussed the utility of DecisionDx-Melanoma in identifying patients with T1 cutaneous melanoma at high risk of SLN positivity and recurrence. The test’s Class 2B result was identified as the strongest predictor of a positive SLN among various risk factors.
DecisionDx-Melanoma is a gene expression profile risk stratification test that integrates tumor biology with clinical and pathologic factors to provide comprehensive and clinically actionable results. The test’s clinical value is backed by extensive research and has been ordered over 150,000 times for patients with cutaneous melanoma, contributing to improved disease management and patient outcomes.
Castle Biosciences continues to lead in innovative diagnostics that guide patient care across various diseases, including skin cancers and uveal melanoma, with active research and development programs aiming to address high clinical needs in other medical conditions.
